化合物Visomitin T4168

Product Introduction
Bioactivity


英文名: Visomitin

描述: Visomitin (SKQ1) 是一种靶向线粒体的抗氧化剂，表现出高效的线粒体穿透能力和有效的抗氧化能力。

细胞实验: Panc02 cells are treated 48 h with different concentrations of Visomitin (SkQ1). Cell viability after Visomitin treatment is measured with an EZ4U Kit as described by the manufacturers. Brie?y, 20,000 cells per well are seeded in 96-wellplates and let grow overnight. Afterwards, cells are treated without the medium exchange. A substrate compound from the kit is added and the cells are further incubated for 5 hr at 37°C to convert the yellow colored tetrazolium to its red formazan derivate by living cells. The absorbance is measured at 450 nm

动物实验: Female C57BL/6 mice are used in this study. For experiments on both acute and chronic pancreatitis, mice are divided in three groups. Group A (acute pancreatitis (AP) n=8; chronic pancreatitis (CP) n=12) is treated with 5?nmol/kg Visomitin (SkQ1), group B (AP n=8; CP n=12) is the untreated control, and group C (AP n=8; CP n=7) is the sham group, which is injected intraperitoneally with 0.9% NaCl instead of cerulein and is therefore the negative control group without pancreatitis. For experiments on acute pancreatitis, mice are pretreated with Visomitin for 8 weeks prior to induction of pancreatitis. Mice designated for experiments on chronic pancreatitis receive Visomitin at the same concentration for 8 weeks in parallel with induction of pancreatitis

体外活性: Direct treatment of tumor infiltrating leukocytes with Visomitin (SkQ1) does not influence their cytotoxicity against Panc02 cells. Visomitin reduces heavily the proliferation of human PDAC cells at 500 nM concentration while not affecting the viability of the cell lines.

体内活性: Regarding systemic angiogenic factors, a decrease in KC was observed in the serum of Pancreatic ductal adenocarcinoma (PDAC) bearing mice in the group of continuous treatment with Visomitin (SkQ1). Treatment of the mice with Visomitin increases the level of VEGF molecules. The amount of MIP1a and prolactin is reduced in all Visomitin treatment groups or after the follow-up treatment, respectively. Also, an increase in the IL-6 and IL-13 amount is found in the Visomitin treated groups. TGF-b amount is decreased in the pretreatment setting. On the contrary, all schemes of the Visomitin treatment decrease the NKT cell percentage. The Visomitin treatment has prolonged the median survival of PDAC-bearing mice, but the difference does not reach the level of significance defined.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/mL (89.05 mM)


关键字: inhibit | Visomitin | Inhibitor | SKQ 1 | Reactive Oxygen Species | SKQ-1

相关产品: Zinc Protoporphyrin | Mefloquine hydrochloride | norbergenin | Hexaconazole | 3-Amino-1,2,4-triazole | Phillygenin | Calycosin-7-O-β-D-glucoside | Ascorbyl palmitate | Ammonium sulfate | Glutathione ethyl ester

相关库: Drug Repurposing Compound Library | Pyroptosis Compound Library | FDA-Approved & Pharmacopeia Drug Library | Anti-Cancer Drug Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Metabolism Compound Library | Preclinical Compound Library

化合物Visomitin T4168信息由TargetMol中国为您提供，如您想了解更多关于化合物Visomitin T4168报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途